Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients

2020 ◽  
pp. 1-11
Author(s):  
Lei Wang ◽  
Yehui Zhou ◽  
Suhua Xia ◽  
Linlin Lu ◽  
Tiantian Dai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Inflammation ◽  
Prognostic Value ◽  
Operable Breast Cancer ◽  
Breast Cancer Patients ◽  
Inflammation Response ◽  
Response Index ◽  
Before And After

Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

2007 ◽  
Vol 12 (6) ◽  
pp. 636-643 ◽  
Author(s):  
Olivier Tacca ◽  
Frédérique Penault‐Llorca ◽  
Catherine Abrial ◽  
Marie‐Ange Mouret‐Reynier ◽  
Inès Raoelfils ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Prognostic Value ◽  
Hormone Receptor Status ◽  
Operable Breast Cancer ◽  
Breast Cancer Patients ◽  
Receptor Status

Prognostic value of a new clinical-genomic model to predict 10-year risk of recurrence in patients with operable breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 530-530
Author(s):  
Lei Lei ◽  
Tzu-Ting Huang ◽  
Andre Ching-Hsuan Chen ◽  
Tzu-Pin Lu ◽  
Skye Hung-Chun Cheng
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Prognostic Model ◽  
Operable Breast Cancer ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Distant Relapse ◽  
Clinical Genomic

530 Background: Searching for a specific biomarker to predict long-term risk of recurrence for all breast cancer subtypes is challenging. DGM-CM6 (Distant Genetic Model-Clinical variable Model 6) is a new clinical-genomic prognostic model developed from the 18-gene panel which was reported previously. This study aims to validate the long-term prognostic value of this new model in all subtypes of operable breast cancer patients. Methods: We included 752 operable breast cancer patients with stage I-III in all subtypes treated in a Cancer Center from 2005 to 2014 as the internal validation (IV) cohort. The median follow-up was 94.1 months. Meanwhile, Affymetrix U133P2 (n = 1139) data obtained from GEO (GSE9195/16391/17907/19615/20711/21653/42568, EMTAB365) were collected as the external validation (EV) dataset. The prognostic effect of DGM-CM6 was then evaluated by uni- and multivariate analyses. The low- and high-risk patients ( < 33 or ≥ 33 as cut-off value) classified by DGM-CM6 were evaluated by the 10-year distant relapse-free interval (DRFI), relapse-free interval (RFI), relapse-free survival (RFS) and distant relapse-free survival (DRFS), respectively. We further compared the predictive performance between DGM-CM6/DGM and PAM50-ROR score in our IV dataset. Results: In the IV dataset, DGM-CM6 was proved to be an independent prognostic factor by multivariate analysis with hazard ratios of 3.1 (1.6-6.0) for RFS (P = 0.0009) and 3.2 (1.6-6.3) for DRFS (P = 0.0009). Significant differences were observed between low- and high-risk groups with 10-year RFI (94.0% vs. 83.5%, P < 0.0001), RFS (90.0% vs. 80.5%, P = 0.0003), DRFI (94.1% vs. 85.0%, P < 0.0001), and DRFS (90.1% vs. 81.9%, P = 0.0004), respectively. The prognostic value of RFS was convinced in the EV dataset (HR = 1.34, P = 0.00052) by the DGM only. According to C-index estimate analysis, DGM appeared to have better performance comparing with PAM50 ROR score in prediction of long-term DR, DRFS, RFI, and RFS in N0 patients (C index for distant recurrence: 0.582 by DGM, 0.528 by ROR). Conclusions: DGM-CM6 could be a new long-term prognostic model to be applied in all subtypes of operable breast cancer patients. Further validation in a large scale of clinical trials is needed.

scholarly journals Dynamic Changes in the Systemic Inflammation Response Index Predict the Outcome of Resectable Gastric Cancer Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Zhenhua Liu ◽  
Haijue Ge ◽  
Zhilong Miao ◽  
Shoupeng Shao ◽  
Hongtai Shi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Systemic Inflammation ◽  
Dynamic Change ◽  
Clinicopathological Parameters ◽  
Original Cohort ◽  
Inflammation Response ◽  
Response Index ◽  
Before And After ◽  
Gastric Cancer Patients

The systemic inflammation response index (SIRI) has been revealed to be closely related to the prognosis of a variety of tumors. Whether the dynamic change in SIRI before and after surgery can be used to judge the prognosis of patients after radical gastrectomy has not yet been studied. In this study, the predictive ability of preoperative SIRI and changes in SIRI before and after surgery for the survival rate of gastric cancer patients was evaluated in two independent cohorts. It was found that SIRI was closely related to TNM staging. The higher the TNM stage, the higher the proportion of patients with a high SIRI. However, SIRI was not related to any other clinicopathological parameters. Kaplan-Meier survival analysis showed that a high SIRI was associated with poor prognosis in gastric cancer patients in the original cohort and in the validation cohort. SIRI, NLR, PLR, and MLR could be used to judge the prognosis of patients with operable gastric cancer. However, multivariate analysis suggested that only SIRI was an independent prognostic factor for patients with operable gastric cancer. In addition, the change in SIRI at 4 to 6 weeks after surgery compared with SIRI before surgery was closely related to the survival of gastric cancer patients. Compared with the unchanged group (absolute variation &lt;50%), gastric cancer patients with a SIRI increase &gt;50% had a worse OS, while patients with a SIRI decrease &gt;50% had a better prognosis. In conclusion, SIRI can be used as a reliable index to evaluate the prognosis of patients with operable gastric cancer, and the dynamic change in SIRI before and after surgery is significantly related to the prognosis of patients with gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document